Tasca Therapeutics Doses First Patient in Phase 1/2 Dose Escalation and Expansion Trial Evaluating CP-383 in Advanced Solid Tumors
TSCA(TSCA) CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #ClinicalTrials--Tasca Therapeutics has dosed the first patient in its Phase 1/2 dose escalation and expansion study of CP-383 in advanced solid tumors.
September 16, 2025Clinical Trials
Read more →